SC79

Catalog No.S7863 Batch:S786302

Print

Technical Data

Formula

C17H17ClN2O5
Molecular Weight 364.78 CAS No. 305834-79-1
Solubility (25°C)* In vitro DMSO 72 mg/mL (197.37 mM)
Ethanol 72 mg/mL (197.37 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
Targets
Akt [1]
In vitro

SC79 suppresses PHAKTM-GFP plasma membrane translocation, and enhances phosphorylation of all three Akt isoforms in HEK293, HeLa, HL60, NB4, and HsSulton (B cells) cells. This compound reduces neuronal excitotoxicity and prevents stroke-induced neuronal death. It restores proliferation of BRAT1 knockdown cells, and reduces the production of superoxide in mitochondria of MitoSox positive cells.

In vivo

In the permanent focal cerebral ischemia mouse model, SC79 (0.04 mg/g, i.p.) enables the cytosolic activation of Akt, and recapitulates the primary cellular function of Akt signaling, resulting in augmented neuronal survival.

Protocol (from reference)

Kinase Assay:

[1]
  • Cytosolic phosphorylation of Akt

    Hela cells are serum starved for 1 hr and treated with IGF (100ng/mL) or SC79 (4 μg/mL) for 30 minutes. Cells are lysed in Lysis buffer containing 250 mM Sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA supplemented with protease inhibitors. Cells are passed through 25G needle several times and kept on ice for 20 minutes. Total cell lysate is taken at this point. Cell lysates are centrifuged at 100,000g for 30 minutes. Supernatant is collected as the cytosolic fraction. Pellet is washed with lysis buffer and represents the membrane fraction. Total cell lysate, cytosolic and membrane fractions are resolved by SDS-PAGE and analyzed for phospho-Akt (S473), Total Akt, Tubulin (cytosolic marker) and Orai1 (membrane marker) by western blotting.
Cell Assay:

[1]
  • Cell lines

    HsSultan and NB4 cells

  • Concentrations

    8 μg/mL

  • Incubation Time

    24 h

  • Method

    HsSultan or NB4 cells (2.5 × 105) are plated in a 24-well plate in 500 μL of phenol red-free RPMI medium supplemented with 10% FBS. After incubation for 24 hours, each compound (8 µg/mL) is added and cultured for overnight (16–20 h). Fifty microliters of MTT solution (5 mg/mL in PBS) are added to each well. Following 2 hrs incubation, the purple formazan crystals are dissolved by directly adding in 500 μL of isopropanol with 0.1 M HCl to each well. After clearing the cell debris by centrifugation, the absorbance is measured at a wavelength of 570 nm.
Animal Study:

[1]
  • Animal Models

    Permanent focal cerebral ischemia mouse model

  • Dosages

    0.04 mg/g

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/22689977/
  • https://pubmed.ncbi.nlm.nih.gov/25070371/

Customer Product Validation

Cells with OGN over-expression were challenged with EGF (100 ng/mL) and pretreated with SC79 (constitutive Akt activator) for 24 h. Western blotting with the significantly altered markers was performed.

Data from [ , , J Exp Clin Cancer Res, 2018, 37(1):41 ]

U251 cells were treated with PAMK-2206-2HCl or SC79 for 24 h. The expression of FoxM1 and MYBL2 were detected by western blotting.

Data from [ , , J Exp Clin Cancer Res, 2017, 36(1):105 ]

cells with OGN over-expression were challenged with EGF (100 ng/ml) and pretreated with SC79 (constitutive Akt activator) for 24 h. Western blotting presented a significant reduction in expression of HIF-1α and VEGF. Data were representative of three independent experiments with one-way ANOVA test.

Data from [ , , EBioMedicine, 2018, 34:35-45 ]

SC79 enhances fusion and myotube formation of L6 myoblasts through upregulation of Akt signaling. Immunofluorescence analysis of L6 myoblasts in the presence of 1 μM SC79 or MK2206 at 3, 5 and 7 days during myogenic differentiation. Staining for myosin heavy chain (MHC, green) marks differentiated cells. Nuclei were counterstained with DAPI (blue). Fusion index, myofiber diameter and number of nuclei per myofiber were measured at 3, 5 and 7 days after differentiation in the presence of 1 μM SC79 or MK2206. Scale bar, 50 μm. The data are presented as the mean ± SD. ⁎P < 0.05 versus blank controls from the same day. MHC, myosin heavy chain.

Data from [ , , Biochim Biophys Acta Mol Basis Dis, 2017, 1863(11):2848-2861 ]

Selleck's SC79 Has Been Cited by 176 Publications

Chemomechanical remodeling of glucocorticoid-sensitive fibroblasts for multimodal synergistic therapy of skin fibrosis [ Cell Rep Med, 2026, 7(2):102592] PubMed: 41707648
Scoparone induces mitophagy and apoptosis via ROS accumulation in pancreatic cancer cells [ Curr Res Toxicol, 2026, 10:100281] PubMed: 41630986
OTUB1/SLC7A11 axis promoted AKT signaling activation to mediate ovarian cancer progression [ Cancer Treat Res Commun, 2026, 46:101116] PubMed: 41610579
ERp46 mitigates lipotoxic ER stress to preserve GLUT2 expression and insulin secretion in β-cells [ Biomed Rep, 2026, 24(2):22] PubMed: 41384131
Small molecules induces dorsal root ganglion satellite glial cells to differentiate into sensory neuron-like cells [ Cells Dev, 2026, 185:204073] PubMed: 41690597
PI3K-Akt signalling regulates Scx-lineage tenocytes and Tppp3-lineage paratenon sheath cells in neonatal tendon regeneration [ Nat Commun, 2025, 16(1):3734] PubMed: 40254618
Autophagy inhibition improves the efficacy of anlotinib and PD-1 inhibitors in the treatment of NSCLC [ J Immunother Cancer, 2025, 13(9)e010812] PubMed: 40983344
YBX1/CD36 positive feedback loop-mediated lipid accumulation drives metabolic dysfunction-associated steatotic liver disease [ Int J Biol Sci, 2025, 21(5):2118-2134] PubMed: 40083711
Artemisinin Suppressed Melanoma Recurrence and Metastasis after Radical Surgery through the KIT/PI3K/AKT Pathway [ Int J Biol Sci, 2025, 21(1):75-94] PubMed: 39744440
Macrophages downregulate NEDD9 to counteract S. Typhimurium- mediated FAK-AKT activation and lysosome inhibition [ Cell Death Dis, 2025, 16(1):445] PubMed: 40506423

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.